Keuangan Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ · Healthcare · Biotechnology · Karyawan: 711 · CEO: Christopher R. Anzalone
- Harga
- $59,90 -0,98%
- Kapitalisasi pasar
- $8,46 M
- Nilai perusahaan
- $9,27 M
- Laporan terakhir
- Q3 '26 diajukan 2026-08-04
- Laporan berikutnya
- 2026-11-24 Estimasi EPS: -$1,52
Pendapatan (TTM)$669 jt+16,8% vs tahun lalu4 kuartal terakhir; batang = tiap kuartal
Margin operasional (TTM)-33,8%-15,0 poin vs tahun laluLaba operasional: -$226 jt
Laba bersih (TTM)-$320 jt-115,6% vs tahun laluSetelah pajak, termasuk keuntungan non-operasional
Arus kas bebas (TTM)-$75,1 jt-326,3% vs tahun laluCapex: $16,1 jt
EPS dilusian (TTM)-$2,24-72,3% vs tahun laluJumlah 4 kuartal terakhir
Kas neto$738 jt+294,4% vs tahun laluKas + investasi jangka pendek - utang
Valuasi & angka utama
- Kapitalisasi pasar
- $8,46 M EV $9,27 M
- Pendapatan
- $669 jt 12 bulan terakhir
- Pertumbuhan pendapatan
- -44% Konsensus FY2026
- Margin laba
- -47,8% Laba bersih / pendapatan, TTM
- P/E
- -26,7× Forward -17,0× (FY2026)
- P/S
- 12,6× Harga / penjualan, TTM
- EV / EBITDA
- -69,4× TTM
- Arus kas bebas
- -$75,1 jt 12 bulan terakhir
- Laba bersih
- -$320 jt 12 bulan terakhir
- Estimasi pendapatan
- $464 jt Konsensus FY2026
- Laba
- 2026-11-24 Estimasi pendapatan: $61,2 jt
- Dividen
- – Tanpa dividen
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-08-04): pendapatan melampaui 70,4%, EPS meleset 6,3%Pendapatan $75,3 jt vs $44,2 jt yang diharapkan (+70,4%); EPS -$1,36 vs -$1,28 (-6,3%).
- Pertumbuhan pendapatan melambat: 171,0% yoyPendapatan Q3 '26: $75,3 jt, rata-rata empat kuartal sebelumnya: 5.187,5%.
- Margin operasional -33,8% (TTM), dibanding tahun lalu: -15,0 poinLaba operasional tumbuh -109,7%, pendapatan tumbuh 16,8%.
- Capex: 2,4% dari pendapatan (tahun lalu 6,9%)$16,1 jt diinvestasikan dalam 4 kuartal terakhir (-59,3% dibanding tahun sebelumnya). Arus kas bebas: -$75,1 jt.
- Jumlah saham dilusian naik dalam setahun: 3,1%Saham dilusian pada Q3 '26: 143 jt, setahun sebelumnya: 139 jt.
- Kas neto: $738 jtKas + investasi jangka pendek: $1,6 M, utang termasuk sewa: $864 jt; tahun lalu kas neto: $187 jt.
Kuartal terakhir: Q3 '26
Kuartal berakhir 2026-06-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q3 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $75,3 jt | $27,8 jt | +171,0% |
| Margin kotor | 100,0% | 100,0% | 0,0 poin |
| Laba operasional | -$170 jt | -$166 jt | -2,7% |
| Margin operasional | -226,0% | -596,2% | +370,2 poin |
| Laba bersih | -$194 jt | -$175 jt | -10,9% |
| EPS dilusian | -$1,36 | -$1,26 | -7,9% |
| Arus kas operasional | -$177 jt | -$155 jt | -14,7% |
| Capex | $3,85 jt | $2,36 jt | +63,0% |
| Arus kas bebas | -$181 jt | -$157 jt | -15,4% |
| R&D | $198 jt | $162 jt | +22,1% |
| Kompensasi berbasis saham | $14,7 jt | $13 jt | +12,9% |
Dilaporkan vs konsensus
2026-08-04| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $75,3 jt | $44,2 jt | +70,4% |
| EPS (basis konsensus) | -$1,36 | -$1,28 | -6,3% |
Dari laporan 2026-08-04 untuk Q3 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanMargin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- -$59,1 jt
- Capex
- -$16,1 jt
- Buyback
- $0
- Dividen
- $0
- Akuisisi
- $0
- Utang neto diterbitkan
- $1,19 M
- Kompensasi berbasis saham
- $70 jt
- Arus kas bebas
- -$75,1 jt
- Dikembalikan ke pemegang saham / FCF
- 0,0%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | -26,7× | – | – |
| EV / EBITDA | -69,4× | 28,8× 1 dari 5 tahun | 28,8× – 28,8× |
| EV / Penjualan | 13,8× | 188,6× | 5,7× – 864,4× |
| Harga / FCF | -112,6× | 36,6× 2 dari 5 tahun | 29,4× – 43,8× |
| Harga / Nilai buku | 18,4× | 11,5× | 8,7× – 15,8× |
| Imbal hasil FCF | -0,9% | -7,5% | -26,0% – 3,4% |
| Imbal hasil modal yang diinvestasikan | -12,1% | -28,3% | -57,4% – 4,6% |
| Imbal hasil ekuitas | -60,5% | -95,6% | -323,3% – -0,3% |
Analis
Target konsensus $101,56 (+69,5%)
rentang $46,00 – $126,00 · peringkat Buy
Beli kuat0
Beli16
Tahan6
Jual0
Jual kuat0
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $464 jt | -44,0% | -$3,52 | -28.781,2% | -17,0× | 12 |
| FY2027 | $330 jt | -28,9% | -$4,86 | -37,8% | -12,3× | 13 |
| FY2028 | $666 jt | +101,8% | -$2,81 | +42,1% | -21,3× | 8 |
| FY2029 | $1,15 M | +72,3% | -$0,74 | +73,8% | -81,4× | 5 |
| FY2030 | $2,04 M | +78,1% | $4,41 | +698,7% | 13,6× | 3 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 228 angka yang ditandai Arrowhead Pharmaceuticals, Inc. dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable, Current | $27,8 jt | $33,1 jt | -16,0% | $17,7 jt | $11,4 jt | +55,2% |
| Accounts Receivable, after Allowance for Credit Loss | $5,8 jt | $9,7 jt | -40,2% | $6,82 jt | $0 | – |
| Accounts Receivable, after Allowance for Credit Loss, Current | $8,56 jt | $9,7 jt | -11,8% | $6,82 jt | $0 | – |
| Accrued Income Taxes, Current | $0 | – | – | $20,8 jt | $0 | – |
| Accrued Liabilities, Current | $86,2 jt | $64,8 jt | +32,9% | $90,4 jt | $63 jt | +43,5% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $97,2 jt | $74,2 jt | +31,0% | $80,2 jt | $58 jt | +38,2% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$1,23 jt | $5,36 jt | -123,0% | $6,44 jt | $4,75 jt | +35,6% |
| Additional Paid in Capital, Common Stock | $2,44 M | $2,12 M | +15,2% | $2,14 M | $1,81 M | +18,5% |
| Adjustments to Additional Paid in Capital, Warrant Issued | $100 jt2026-03-31 | – | – | $25 jt | – | – |
| Amortization of Debt Issuance Costs | $766 rb | $0 | – | – | – | – |
| Amortization of Intangible Assets | $400 rb | $400 rb | 0,0% | $1,7 jt | $1,7 jt | 0,0% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 14,7 jt | 5,95 jt | +146,6% | 5,02 jt | 4,74 jt | +6,0% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $14,9 jt | $13 jt | +14,0% | $63,4 jt | $74 jt | -14,3% |
| Assets | $2,11 M | $1,38 M | +53,0% | $1,39 M | $1,14 M | +21,5% |
| Assets, Current | $1,67 M | $947 jt | +76,5% | $951 jt | $695 jt | +36,7% |
| Assets, Fair Value Disclosure | $1,58 M | – | – | – | – | – |
| Capital Expenditures Incurred but Not yet Paid | $750 rb | -$12 rb | +6.350,0% | $277 rb | $4,21 jt | -93,4% |
| Cash and Cash Equivalents, Fair Value Disclosure | $32,2 jt | – | – | – | – | – |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $54,8 jt | $130 jt | -57,8% | $227 jt | $103 jt | +120,6% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect | -$134 jt | -$56 jt | -139,7% | $124 jt | -$12,4 jt | +1.101,9% |
| Class of Warrant or Right, Exercise Price of Warrants or Rights | – | – | – | $0,002024-11-25 | – | – |
| Class of Warrant or Right, Number of Securities Called by Warrants or Rights | – | – | – | 917 rb2024-11-25 | – | – |
| Common Stock, Par or Stated Value Per Share | $0,00 | $0,00 | 0,0% | $0,00 | $0,00 | 0,0% |
| Common Stock, Shares Authorized | 290 jt | 290 jt | 0,0% | 290 jt | 290 jt | 0,0% |
| Common Stock, Shares, Issued | 144 jt | 138 jt | +4,1% | 136 jt | 124 jt | +9,1% |
| Common Stock, Shares, Outstanding | 141 jt | 138 jt | +2,2% | 136 jt | 124 jt | +9,1% |
| Common Stock, Value, Issued | $237 rb | $230 rb | +3,0% | $231 rb | $217 rb | +6,5% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest | $15,6 jt | -$3,41 jt | +556,6% | $31,7 jt | -$10,2 jt | +411,2% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$196 jt | -$174 jt | -12,6% | -$141 jt2021-09-30 | -$84,1 jt | -67,5% |
| Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest | -$181 jt | -$178 jt | -1,7% | $31,8 jt | -$602 jt | +105,3% |
| Contract with Customer, Asset, after Allowance for Credit Loss, Current | $10,2 jt | – | – | – | – | – |
| Contract with Customer, Liability | $2,4 jt2025-09-30 | $0 | – | $2,4 jt | $0 | – |
| Contract with Customer, Liability, Current | $94,6 jt | $23 jt | +311,7% | $2,4 jt | $0 | – |
| Contract with Customer, Liability, Noncurrent | $31,7 jt | $0 | – | $02023-09-30 | $56 jt | -100,0% |
| Contract with Customer, Liability, Revenue Recognized | -$46,6 jt | -$27,6 jt | -68,8% | – | – | – |
| Convertible Debt | $683 jt | – | – | – | – | – |
| Convertible Debt, Noncurrent | $683 jt | – | – | – | – | – |
| Current Federal Tax Expense (Benefit) | – | – | – | $21,4 jt | $148 rb | +14.386,5% |
| Current Foreign Tax Expense (Benefit) | – | – | – | $35 rb | -$3,29 jt | +101,1% |
| Current Income Tax Expense (Benefit) | – | – | – | $21,4 jt | -$2,77 jt | +874,1% |
| Current State and Local Tax Expense (Benefit) | – | – | – | -$56 rb | $375 rb | -114,9% |
| Debt Securities, Available-for-sale | $1,55 M | $771 jt | +100,8% | $693 jt | $578 jt | +19,8% |
| Debt Securities, Available-for-sale, Amortized Cost, Current | $1,55 M | $769 jt | +102,1% | $690 jt | $577 jt | +19,5% |
| Debt Securities, Available-for-sale, Current | $1,55 M | $771 jt | +100,8% | $693 jt | $578 jt | +19,8% |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year | $605 jt | $225 jt | +169,6% | – | – | – |
| Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | $224 jt2025-09-30 | $578 jt | -61,2% | $224 jt | $578 jt | -61,2% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Tax Assets, Deferred Income | $171 jt2025-09-30 | $81,6 jt | +110,0% | $171 jt | $81,6 jt | +110,0% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $1,03 jt2025-09-30 | $1,38 jt | -25,3% | $1,03 jt | $1,38 jt | -25,3% |
| Deferred Tax Assets, Gross | $563 jt2025-09-30 | $473 jt | +19,0% | $563 jt | $473 jt | +19,0% |
| Deferred Tax Assets, Net | $02025-09-30 | $0 | – | $0 | $0 | – |
| Deferred Tax Assets, Operating Loss Carryforwards | $70,9 jt2025-09-30 | $103 jt | -31,0% | $70,9 jt | $103 jt | -31,0% |
| Deferred Tax Assets, Other | $948 rb2025-09-30 | $2,84 jt | -66,7% | $948 rb | $2,84 jt | -66,7% |
| Deferred Tax Assets, Tax Credit Carryforwards | $48,9 jt2025-09-30 | $85,4 jt | -42,8% | $48,9 jt | $85,4 jt | -42,8% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits | $4,25 jt2025-09-30 | $4,08 jt | +4,3% | $4,25 jt | $4,08 jt | +4,3% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $9,18 jt2025-09-30 | $11 jt | -16,4% | $9,18 jt | $11 jt | -16,4% |
| Deferred Tax Assets, Valuation Allowance | $498 jt2025-09-30 | $449 jt | +10,8% | $498 jt | $449 jt | +10,8% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, dan estimasi distandardisasi dari laporan perusahaan. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-Q 2025-12-31, 10-K 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-Q 2024-12-31, 10-K 2024-09-30, 10-Q 2024-06-30
Data per 2026-11-02